Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2018 Nov 15

PMID 30426090

Citations 14

Authors

Radica Zivkovic Zaric

Jasmina Milovanovic

Nikola Rosic

Dragan Milovanovic

Dejana Ruzic Zecevic

Marko Folic

Slobodan Jankovic

Affiliations

Soon will be listed here.

Abstract

There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may affect vancomycin pharmacokinetics in groups of patients with normal renal function and in those with chronic kidney failure. The study used a population pharmacokinetic modeling approach, based on plasma vancomycin concentrations and other data from 78 patients with chronic kidney failure and 32 patients with normal renal function. The model was developed using NONMEM software and validated by bootstrapping. The final model for patients with impaired kidney function was described by the following equation: CL (L/h) = 0.284 + 0.000596 x DD + 0.00194 x AST, and that for the patients with normal kidney function by: CL (L/h) = 0.0727 + 0.205 x FIB. If our results are confirmed by new studies on two similar populations, these factors could be considered when dosing vancomycin in patients with chronically damaged kidneys, as well as in patients with normal kidneys who frequently require high doses of vancomycin.

Citing Articles

Pharmacokinetic effect of disease severity and use of extracorporeal membrane oxygenation in critically ill Asian patients receiving vancomycin.

Avachat C, Hung P, Birnbaum A, Healy D, Sherwin C, Lin A Front Pharmacol. 2025; 16:1506793.

PMID: 40078297 PMC: 11897554. DOI: 10.3389/fphar.2025.1506793.

Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi Patients.

Alqurain A, Alrashidi L, Aloraifej S, Alkhalifah M, Alsayed H, Abohelaika S Drug Des Devel Ther. 2024; 18:6185-6198.

PMID: 39722680 PMC: 11669282. DOI: 10.2147/DDDT.S496512.

Drug-Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians.

Hincu S, Apetroaei M, Stefan G, Faca A, Arsene A, Mahler B Pharmaceutics. 2024; 16(9).

PMID: 39339174 PMC: 11434876. DOI: 10.3390/pharmaceutics16091137.

Drug-induced linear IgA bullous dermatosis with extensive mucosal involvement.

Starzyk T, Nikakis J, Ross R JAAD Case Rep. 2024; 52:77-79.

PMID: 39319191 PMC: 11421359. DOI: 10.1016/j.jdcr.2024.07.021.

Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment.

Ahmed K, Ibrahim A, Gonzalez D, Nur A Drug Des Devel Ther. 2024; 18:81-95.

PMID: 38260090 PMC: 10800288. DOI: 10.2147/DDDT.S432439.

References

Jarkowski 3rd A, Forrest A, Sweeney R, Tan W, Segal B, Almyroudis N . Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2011; 18(1):91-6. DOI: 10.1177/1078155211402107. View

Ji X, Ji S, He X, Zhu X, Chen R, Lu W . Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacol Sin. 2017; 39(2):286-293. PMC: 5800467. DOI: 10.1038/aps.2017.57. View

Sima M, Hartinger J, Cikankova T, Slanar O . Importance of vancomycin loading doses in intermittent infusion regimens. J Infect Chemother. 2017; 24(4):247-250. DOI: 10.1016/j.jiac.2017.11.002. View

Sanchez J, Dominguez A, Lane J, Anderson P, Capparelli E, Cornejo-Bravo J . Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010; 48(8):525-33. DOI: 10.5414/cpp48525. View

Al-Kofide H, Zaghloul I, Al-Naim L . Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2009; 16(4):245-50. DOI: 10.1177/1078155209355847. View

Nakamura T, Hashimoto Y, Kokuryo T, Inui K . Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharm Res. 1998; 15(5):734-8. DOI: 10.1023/a:1011971019868. View

Rybak M, Lomaestro B, Rotschafer J, Moellering R, Craig W, Billeter M . Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49(3):325-7. DOI: 10.1086/600877. View

Garaud J, Regnier B, Inglebert F, Faurisson F, Bauchet J, Vachon F . Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984; 14 Suppl D:53-7. DOI: 10.1093/jac/14.suppl_d.53. View

Albanese J, Leone M, Bruguerolle B, Ayem M, Lacarelle B, Martin C . Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000; 44(5):1356-8. PMC: 89870. DOI: 10.1128/AAC.44.5.1356-1358.2000. View

10.

Lodise T, Lomaestro B, Graves J, Drusano G . Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52(4):1330-6. PMC: 2292536. DOI: 10.1128/AAC.01602-07. View

11.

Moore J, Zakai N, Mahalingam M, Griffin R, Irvin M, Safford M . Hemostasis biomarkers and risk of sepsis: the REGARDS cohort. J Thromb Haemost. 2016; 14(11):2169-2176. PMC: 5503746. DOI: 10.1111/jth.13446. View

12.

Medellin-Garibay S, Romano-Moreno S, Tejedor-Prado P, Rubio-Alvaro N, Rueda-Naharro A, Blasco-Navalpotro M . Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients. Antimicrob Agents Chemother. 2017; 61(12). PMC: 5700364. DOI: 10.1128/AAC.01249-17. View

13.

Bamgbola O . Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016; 7(3):136-47. PMC: 4892398. DOI: 10.1177/2042018816638223. View

14.

Jeffres M . The Whole Price of Vancomycin: Toxicities, Troughs, and Time. Drugs. 2017; 77(11):1143-1154. PMC: 5501899. DOI: 10.1007/s40265-017-0764-7. View

15.

Roberts J, Lipman J . Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009; 37(3):840-51. DOI: 10.1097/CCM.0b013e3181961bff. View

16.

Saugel B, Gramm C, Wagner J, Messer M, Lahmer T, Meidert A . Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. J Crit Care. 2014; 29(3):351-5. DOI: 10.1016/j.jcrc.2013.12.007. View

17.

Purwonugroho T, Chulavatnatol S, Preechagoon Y, Chindavijak B, Malathum K, Bunuparadah P . Population pharmacokinetics of vancomycin in Thai patients. ScientificWorldJournal. 2012; 2012:762649. PMC: 3322481. DOI: 10.1100/2012/762649. View

18.

Campassi M, Gonzalez M, Masevicius F, Risso Vazquez A, Moseinco M, Navarro N . [Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment]. Rev Bras Ter Intensiva. 2014; 26(1):13-20. PMC: 4031886. DOI: 10.5935/0103-507x.20140003. View

19.

Morbitzer K, Jordan J, Sullivan K, Durr E, Olm-Shipman C, Rhoney D . Vancomycin Pharmacokinetic Parameters in Patients with Hemorrhagic Stroke. Neurocrit Care. 2016; 25(2):250-7. DOI: 10.1007/s12028-016-0264-8. View

20.

Lin W, Wu W, Jiao Z, Lin R, Jiang C, Huang P . Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol. 2015; 72(1):29-37. DOI: 10.1007/s00228-015-1952-6. View